By the end of 2033, the chronic idiopathic constipation treatment market is expected to have grown from a projected value of US$ 9.4 billion in 2023 to US$ 19.7 billion, expanding quickly at a CAGR of 7.5%. When a person has difficult, infrequent, and/or suboptimal defecation, it is known as chronic idiopathic constipation (CIC), a common functional bowel disorder. Chronic idiopathic constipation is becoming more common due to factors like sedentary lifestyles, growing anti-inflammatory medicine use, and a rapid decline in dietary fibre consumption. Download Sample Copy of This Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=8517 Additionally, rising rate of the ageing population, sedentary lifestyles, and dietary changes are contributing to the increasing burden of CIC, thereby driving the demand for treatment options. Fiber supplements, laxatives, stool softeners, and prokinetic agents are commonly used as medications in the management of CIC. Furthermore, advancements in digital health technologies are also shaping the future of chronic idiopathic constipation treatment. Mobile applications, wearable devices, and remote monitoring tools are being developed to help patients track their bowel movements, diet, and exercise habits, and provide personalized recommendations for managing CIC.
8/7/2023Through 2032, the preimplantation genetic testing market is anticipated to develop at a CAGR of around 9% and reach a significant market size. Growth opportunities are expanding as a result of the rising prevalence of genetic illnesses. The market is anticipated to reach US$ 653.52 million by 2022 and will continue to grow, reaching US$ 1,420 million by 2032. Download Free Sample Copy of This Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=292 The biggest benefit offered by preimplantation testing is it offers an opportunity to conceive a pregnancy unaffected by genetic conditions. Researchers and healthcare institutes are trying to find new methods and techniques using the latest technology to minimize various risks associated with preimplantation genetic testing. Key Highlights
8/7/2023According to Fact.MR’s most recent industry analysis, implanted medical device market sales are expected to grow globally between 2022 and 2027 at a compound annual growth rate of 6.1%. The market for implantable medical devices is expanding as a result of increased chronic illness prevalence, an ageing population, and improvements in active implanted medical devices. Additionally, increased funding and investments in the creation of technologically advanced products, elevated awareness of advancements in medical implants, and an increase in the use of neurostimulators are all contributing to market expansion. Download Sample Copy of This Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=7728 Incidence of cardiovascular diseases is rising, and obesity rates are high, which are the main drivers that are likely to fuel market growth for implantable medical devices. Medical professionals and patients can monitor their illnesses to receive an early update with the use of implantable medical devices. These wireless, automated devices assess a patient’s sensitivity to a prescribed medicine dosage. The rising prevalence of neurological illnesses such as Parkinson’s disease and spasticity is driving the demand for active implantable medical devices.
8/7/2023Anaesthesia monitoring equipment market sales are anticipated to grow globally between 2022 and 2027 at a strong CAGR of 9.1%. The market for anaesthesia monitoring devices is currently worth US$ 2.2 billion. Since there has been a noticeable rise in the prevalence of chronic diseases, more surgeries are being conducted, which increases the demand for anaesthesia apparatus, including anaesthesia monitoring devices. A growing elderly population, rising healthcare costs, and product technology developments are further variables that may boost demand for anaesthesia monitoring devices. The expensive cost of anaesthesia monitoring equipment, however, is anticipated to limit market potential to some degree. Download Sample Copy of This Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=7683 Anesthesia monitoring device manufacturing companies are focusing on the expansion of their product portfolios and are also expanding their business scope by gaining new approvals from regulatory authorities. In April 2022, GE Healthcare, a leading name in the medical industry, announced that it had received pre-market approval from the U.S. FDA for its new software to deliver general anesthesia. The End-Tidal (Et) Control software is cleared to be used on GE’s Aisys CS2 Anesthesia Delivery System.
8/7/2023or
By clicking below, you agree to our terms of service.
New to HackMD? Sign up